iLEADS BMS presents the effects of its novel FXR agonist in Physiogenex’s ALD/MetALD hamster models – check the poster content here

If you are interested to evaluate your novel therapies with Physiogenex, feel free to contact us to discuss your next preclinical study.

About us

 Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.

We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis), cardiovascular and renal complications.